As reported in the last GF0 issue # 300 here, the OIG’s Progress report mentioned challenges it faced in 2016. The report also mentions some other issues which have emerged in the latter part of 2016 which if not addressed, could pose problems in achieving its operational objectives and targets into 2017.
The ED of the Global Fund reports on how the Fund intends to increase programmatic quality and efficiency
In his report to the Board, Executive Director Dr Mark Dybul, highlighted that in order for the Fund to maximize impact at the country level, the Fund must explore ways to improve program quality and efficiency from design to implementation. Dr Dybul stated in the report that the approach it is taking builds upon the Program Quality and Efficiency project it developed in 2015 which aims to improve health program outcomes.
In preparation for the 36th Global Fund Board meeting that took place on 16 to 17 November 2016, the Africa constituencies Bureau convened from 31 October to 1 November 2016 in Kigali, Rwanda to look at critical issues brought to the attention of the board.
Executive Director of Global Fund highlights efforts to increase impact in the fight against TB and MDR-TB
One of the major themes in the Executive Director’s Report is that multi-drug resistant TB is creating a real threat to global health security and now is the time for a rapid and urgent response on TB. The disease has become a public health crisis as more people die from drug-resistant TB than any other antimicrobial resistant agent.
In October 2016, the Global Fund Board has approved $56.6 million for six grants emanating from concept notes submitted by four countries. Of the $56.6 million, $37.2 million represented new money; the balance was existing funding that has been approved prior to the new funding model (NFM) but was nevertheless included in the NFM allocations to countries. and one regional grant.
Following the Global Fund’s recent replenishment in September, the country eligibility list for the 2017-2019 grant cycle has been published. This list identifies the countries and disease components that are eligible to receive funding from the Global Fund for the next three years.
Findings conducted by The Observer, a Kampala based newspaper, indicate that instances of expired medicines and health supplies in Uganda is still rampant, and that expired drugs were still on the shelves at various health facilities during a recent survey conducted by the newspaper.
In October 2015, the World Health Organization reported that the Millennium Development Goal (MDG) to halt and reverse TB incidence (MDG 6c) was achieved on a worldwide basis, in each of WHO’s six regions and in 16 of the WHO’s 22 high-burden countries. While this progress is commendable, recent evidence suggests the trend may be reversing.
Since entering the New Funding Model (NFM) as an early applicant in 2013, Zimbabwe has been a unique case for Global Fund investments. The country submitted a single HIV concept note in April 2013 (before integrated HIV/TB concept notes were encouraged), was granted $311.2 million, and began implementation in January 2014.